Cite
Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa opioid receptor agonist for the treatment of pruritus.
MLA
Spencer, Robert H., et al. “Impact of Renal Impairment on the Pharmacokinetic Profile of Intravenous Difelikefalin, a Kappa Opioid Receptor Agonist for the Treatment of Pruritus.” BMC Nephrology, vol. 25, no. 1, Oct. 2024, p. 351. EBSCOhost, https://doi.org/10.1186/s12882-024-03790-w.
APA
Spencer, R. H., Noonan, P. K., Marbury, T., & Menzaghi, F. (2024). Impact of renal impairment on the pharmacokinetic profile of intravenous difelikefalin, a kappa opioid receptor agonist for the treatment of pruritus. BMC Nephrology, 25(1), 351. https://doi.org/10.1186/s12882-024-03790-w
Chicago
Spencer, Robert H, Patrick K Noonan, Thomas Marbury, and Frédérique Menzaghi. 2024. “Impact of Renal Impairment on the Pharmacokinetic Profile of Intravenous Difelikefalin, a Kappa Opioid Receptor Agonist for the Treatment of Pruritus.” BMC Nephrology 25 (1): 351. doi:10.1186/s12882-024-03790-w.